You just read:

Connect Biopharma Reports Positive Topline Data from Moderate-to-severe Atopic Dermatitis (AD) Phase 1b Study of CBP-201

News provided by

Connect Biopharmaceuticals

Jan 08, 2020, 06:00 ET